PDGFRA is mutated in 11.43% of gastrointestinal stromal tumor patients [3].

PDGFRA is an inclusion criterion in 11 clinical trials for gastrointestinal stromal tumor, of which 10 are open and 1 is closed. Of the trials that contain PDGFRA status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 4 are phase 3 (3 open) [4].

Dasatinib, imatinib, and sunitinib are currently approved for use in patients with PDGFRA mutation in gastrointestinal stromal tumor [4].

Imatinib, avapritinib, and crenolanib are the most frequent therapies in gastrointestinal stromal tumor trials with PDGFRA alterations as inclusion criteria [4].

Imatinib is currently approved for use in patients with PDGFRA mutation in chronic myelomonocytic leukemia [4].

Imatinib is currently approved for use in patients with PDGFRA mutation in myelodysplastic/myeloproliferative neoplasm [4].

PDGFRA is mutated in 4.73% of malignant solid tumor patients [3].

PDGFRA is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 14 are open and 1 is closed. Of the trials that contain PDGFRA status and malignant solid tumor as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 7 are phase 2 (7 open) [4].

Olaparib, vemurafenib, and palbociclib are the most frequent therapies in malignant solid tumor trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 3.97% of non-small cell lung carcinoma patients [3].

PDGFRA is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 8 are open and 1 is closed. Of the trials that contain PDGFRA status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [4].

Selumetinib, akt inhibitor mk2206, and mgcd516 are the most frequent therapies in non-small cell lung carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 1.43% of breast carcinoma patients [3].

PDGFRA is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PDGFRA status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

Fulvestrant, pi3k/mtor inhibitor ly3023414, and vistusertib are the most frequent therapies in breast carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 0.73% of cancer patients [3].

PDGFRA is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain PDGFRA status and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 2 are phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in cancer trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain PDGFRA status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [4].

Pi3k/mtor inhibitor ly3023414, olaparib, and palbociclib are the most frequent therapies in non-hodgkin lymphoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 1.98% of head and neck squamous cell carcinoma patients [3].

PDGFRA is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PDGFRA status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

Mgcd516, abemaciclib, and alpelisib are the most frequent therapies in head and neck squamous cell carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA status and multiple myeloma as inclusion criteria, 3 are phase 2 (3 open) [4].

Palbociclib, vemurafenib, and cobimetinib are the most frequent therapies in multiple myeloma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 10.16% of glioblastoma patients [3].

PDGFRA is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and glioblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

Atezolizumab, crenolanib, and ipatasertib are the most frequent therapies in glioblastoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 5.58% of squamous cell lung carcinoma patients [3].

PDGFRA is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, vistusertib, and abemaciclib are the most frequent therapies in squamous cell lung carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 4.48% of endometrial carcinoma patients [3].

PDGFRA is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, vistusertib, and abemaciclib are the most frequent therapies in endometrial carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 5.68% of small cell lung carcinoma patients [3].

PDGFRA is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PDGFRA status and small cell lung carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in small cell lung carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 3.25% of glioma patients [3].

PDGFRA is an inclusion criterion in 2 clinical trials for glioma, of which 1 is open and 1 is closed. Of the trials that contain PDGFRA status and glioma as inclusion criteria, 2 are phase 2 (1 open) [4].

PDGFRA is mutated in 0.6% of pancreatic carcinoma patients [3].

PDGFRA is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in pancreatic carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 18.18% of diffuse intrinsic pontine glioma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 6.82% of ovarian carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in ovarian carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 6.38% of melanoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in melanoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 4.55% of nasal cavity and paranasal sinus carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 3.33% of malignant salivary gland neoplasm patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 3.1% of urothelial carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 1.76% of adenocarcinoma of the gastroesophageal junction patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 3.45% of nasopharyngeal carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 2.62% of thyroid gland carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in thyroid gland carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 1.28% of histiocytic and dendritic cell neoplasm patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

Pi3k/mtor inhibitor ly3023414 is the most frequent therapy in histiocytic and dendritic cell neoplasm trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 1.26% of colorectal carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in colorectal carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 1.19% of lymphoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Cetuximab, cobimetinib, and crizotinib are the most frequent therapies in lymphoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 0.92% of gastric carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 0.98% of gastric adenocarcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

PDGFRA is mutated in 0.83% of prostate carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

Everolimus and placebo are the most frequent therapies in prostate carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 1.07% of renal cell carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

Vistusertib and selumetinib are the most frequent therapies in renal cell carcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is mutated in 0.64% of esophageal carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 0.63% of hepatocellular carcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is mutated in 0.6% of cholangiocarcinoma patients [3].

PDGFRA is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Vistusertib, adavosertib, and capivasertib are the most frequent therapies in cholangiocarcinoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

Blinatumomab, dasatinib, and mercaptopurine are the most frequent therapies in B-cell acute lymphoblastic leukemia trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Axitinib, bosutinib, and cobimetinib are the most frequent therapies in B-cell non-hodgkin lymphoma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

PDGFRA is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

Pi3k/mtor inhibitor ly3023414, abemaciclib, and cisplatin are the most frequent therapies in peritoneal mesothelioma trials with PDGFRA alterations as inclusion criteria [4].

PDGFRA is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in thymic carcinoma trials with PDGFRA alterations as inclusion criteria [4].